These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 27749424)
1. Small Bowel Carcinoid: The "Dancing Bowel Sign" on 18F-FDOPA PET/CT. Helali M; Heimburger C; Rohr S; Goichot B; Imperiale A Clin Nucl Med; 2016 Dec; 41(12):944-945. PubMed ID: 27749424 [TBL] [Abstract][Full Text] [Related]
2. The Added Diagnostic Value of Addeo P; Poncet G; Goichot B; Leclerc L; Brigand C; Mutter D; Romain B; Namer IJ; Bachellier P; Imperiale A J Gastrointest Surg; 2018 Apr; 22(4):722-730. PubMed ID: 29235002 [TBL] [Abstract][Full Text] [Related]
3. PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting. Yakemchuk VN; Jager PL; Chirakal R; Reid R; Major P; Gulenchyn KY Nucl Med Commun; 2012 Mar; 33(3):322-30. PubMed ID: 22183015 [TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. Minn H; Kemppainen J; Kauhanen S; Forsback S; Seppänen M PET Clin; 2014 Jan; 9(1):27-36. PubMed ID: 25029931 [TBL] [Abstract][Full Text] [Related]
13. Cardiac Metastases of Small-Bowel Carcinoid El Ghannudi S; Ben Abdelghani M; Germain P; Blondet C; Romain B; Imperiale A Circ Cardiovasc Imaging; 2019 Feb; 12(2):e008405. PubMed ID: 30744393 [No Abstract] [Full Text] [Related]
14. Multifocal Small Bowel Carcinoid: Evaluation by 68Ga-DOTATATE PET. Clark M; Nathan M; Broski SM Clin Nucl Med; 2019 Apr; 44(4):e308-e310. PubMed ID: 30762820 [TBL] [Abstract][Full Text] [Related]
15. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062 [TBL] [Abstract][Full Text] [Related]
16. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? Montravers F; Grahek D; Kerrou K; Ruszniewski P; de Beco V; Aide N; Gutman F; Grangé JD; Lotz JP; Talbot JN J Nucl Med; 2006 Sep; 47(9):1455-62. PubMed ID: 16954553 [TBL] [Abstract][Full Text] [Related]
17. High Tumor Uptake on De Rycke O; Perrier M; Ouvrard É; Mennetrey C; Lachachi C; Bando-Delaunay A; Morland D; Goichot B; Taieb D; Walter T; Cadiot G; Cros J; Hentic O; Ruszniewski P; Lebtahi R; Imperiale A; de Mestier L J Nucl Med; 2023 Nov; 64(11):1699-1705. PubMed ID: 37652547 [TBL] [Abstract][Full Text] [Related]
18. Best sensitivity of Testart Dardel N; Montravers F; Triviño-Ibañez E; Gauthé M; Houry S; Talbot JN Rev Esp Med Nucl Imagen Mol; 2016; 35(6):402-405. PubMed ID: 27246293 [TBL] [Abstract][Full Text] [Related]
19. Surgical Principles in the Management of Small Bowel Neuroendocrine Tumors. Gangi A; Anaya DA Curr Treat Options Oncol; 2020 Aug; 21(11):88. PubMed ID: 32862334 [TBL] [Abstract][Full Text] [Related]
20. [Assessment of a neuroendocrine tumour by 111In-pentetreotid scintigraphy and PET with 18FFDOPA and 18F-FDG]. Plaza P; Montravers F; Aide N; Carrera D; Kerrou K; Ferran N; Grahek D; Talbot JN Rev Esp Med Nucl; 2004; 23(6):421-4. PubMed ID: 15625060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]